WALDEN UNIVERSITY | NURS 6521 - Advanced Pharmacology Midterm Exam - Spring 2026/2027 - Set 3
Walden University
NURS 6521: Advanced Pharmacology
Midterm Examination - Spring 2026/2027
Set 3 - Complete Questions and Answers
Total Questions: 100 | Format: Multiple Choice (4 options) | Cognitive Levels: 25% Recall, 55% Application, 20% Analysis
Aligned with 2026-2027 Advanced Practice Nursing (APN) Pharmacology Competencies and current FDA prescribing
guidelines
Examination Instructions: Each item contains a clinical scenario or pharmacology concept followed by four options (A-D).
Select the SINGLE most appropriate answer. Rationales follow each question explaining why the correct option is right
and why each distractor is wrong, including relevant pharmacokinetic principles, pharmacodynamic mechanisms,
patient-specific factors, monitoring parameters, and evidence-based prescribing guidelines. Items marked [CORRECT]
identify the designated answer; rationales cite current FDA black box warnings, Beers Criteria (2023), GDMT heart failure
guidelines (AHA/ACC 2022 updated), ADA Standards of Care (2024-2025), and CDC Antimicrobial Stewardship guidance.
Section 1: Pharmacokinetics and Pharmacodynamics (Q1-Q15) - Absorption, Distribution,
Metabolism, Excretion, and Receptor Theory
Q1: A 68-year-old female is prescribed propranolol 40 mg PO daily for essential hypertension. Compared
with the same dose given intravenously, the oral dose produces a significantly lower peak plasma
concentration. Which pharmacokinetic property BEST explains this observation?
A. The drug undergoes extensive first-pass hepatic metabolism, reducing systemic bioavailability
[CORRECT]
B. Propranolol is highly ionized in the gastric lumen, preventing absorption across enterocytes
C. The drug exhibits a large volume of distribution, sequestering it in adipose tissue
D. P-glycoprotein efflux at the renal tubule accelerates elimination after oral dosing
Correct Answer: A
Rationale: Bioavailability (F) describes the fraction of administered drug reaching systemic circulation unchanged.
Propranolol is a high-extraction-ratio drug metabolized extensively by hepatic CYP2D6 and CYP1A2 during first-pass
metabolism, so oral bioavailability is only about 25-35% versus 100% IV. Option B is incorrect because propranolol is a
weak base that is sufficiently lipophilic in its nonionized fraction to cross enterocytes. Option C confuses distribution
with bioavailability; Vd affects concentration at steady state but not the fraction reaching circulation. Option D describes
a post-absorption elimination process, not the difference between PO and IV peak concentrations.
NURS 6521 Midterm - Set 3 - 100 Questions Page 1 Confidential - For Examination Use
,WALDEN UNIVERSITY | NURS 6521 - Advanced Pharmacology Midterm Exam - Spring 2026/2027 - Set 3
Q2: A patient receiving IV nitroglycerin for unstable angina is switched to an oral nitrate preparation. The
prescriber selects isosorbide dinitrate rather than nitroglycerin tablets. Which pharmacokinetic rationale
supports this decision?
A. Nitroglycerin undergoes nearly complete first-pass hepatic metabolism, rendering oral tablets ineffective
[CORRECT]
B. Isosorbide dinitrate has a larger volume of distribution, prolonging its half-life
C. Nitroglycerin is unstable in gastric pH and degrades before absorption
D. Isosorbide dinitrate does not require hepatic activation to become pharmacologically active
Correct Answer: A
Rationale: Nitroglycerin has an oral bioavailability of less than 1% because of extensive first-pass metabolism by
hepatic organic nitrate reductases, so oral nitroglycerin tablets are clinically useless. Isosorbide dinitrate and mononitrate
are not substrates for these high-capacity enzymes and therefore retain oral bioavailability. Option B incorrectly
attributes the choice to Vd rather than bioavailability. Option C is incorrect; nitroglycerin is not primarily degraded by
gastric acid. Option D is true but irrelevant; nitroglycerin itself is active and requires no prodrug conversion.
Q3: A 55-year-old male weighing 70 kg receives a 500 mg loading dose of phenytoin IV. The drug's volume of
distribution is 0.7 L/kg. Assuming complete bioavailability and instant distribution, what is the EXPECTED
peak plasma concentration?
A. 5.0 mg/L (5 mcg/mL)
B. 7.1 mg/L (7.1 mcg/mL)
C. 10.2 mg/L (10.2 mcg/mL) [CORRECT]
D. 20.0 mg/L (20 mcg/mL)
Correct Answer: C
Rationale: Using Cp = Dose / Vd: Vd = 0.7 L/kg x 70 kg = 49 L. Cp = 500 mg / 49 L = 10.2 mg/L (10.2 mcg/mL). This
places the patient within the lower end of the therapeutic range for phenytoin (10-20 mcg/mL). Option A miscalculates
by applying Vd incorrectly. Option B reflects a math error (failing to divide dose by Vd). Option D would be the upper
limit of the therapeutic range but corresponds to about 1000 mg. Therapeutic drug monitoring is critical for phenytoin
because of its nonlinear Michaelis-Menten kinetics.
Q4: A patient with chronic atrial fibrillation is started on digoxin 0.25 mg PO daily without a loading dose.
The drug's half-life is approximately 36 hours. Approximately how long will it take to reach steady-state
plasma concentrations?
A. 12 hours (one third of a half-life)
B. 36 hours (one half-life)
C. 72-108 hours (two to three half-lives)
D. 180-216 hours (five to six half-lives) [CORRECT]
Correct Answer: D
Rationale: The general pharmacokinetic principle is that steady state is achieved after approximately 4-5 half-lives of
repeated dosing. For digoxin, with t1/2 = 36 hours, steady state is reached in roughly 5 x 36 = 180 hours, or about 7.5
days. Options A, B, and C are too short; partial accumulation occurs but not steady state. Without a loading dose, the
patient requires nearly a week before therapeutic digoxin levels are attained, which is why loading doses (0.5-1.0 mg in
divided doses) are used when rapid digitalization is required.
NURS 6521 Midterm - Set 3 - 100 Questions Page 2 Confidential - For Examination Use
,WALDEN UNIVERSITY | NURS 6521 - Advanced Pharmacology Midterm Exam - Spring 2026/2027 - Set 3
Q5: Three investigational compounds are compared for safety margin. Drug X has an LD50 of 80 mg and
ED50 of 8 mg; Drug Y has LD50 of 50 mg and ED50 of 25 mg; Drug Z has LD50 of 200 mg and ED50 of 20
mg. Which statement BEST reflects the relative safety of these agents?
A. Drug X has the widest TI and is the safest agent
B. Drug Y is safest because it has the lowest LD50
C. Drug Z has a TI of 10 and is among the safer agents [CORRECT]
D. All three drugs have equivalent safety profiles
Correct Answer: C
Rationale: Therapeutic Index (TI) = LD50 / ED50. Drug X: 80/8 = 10. Drug Y: 50/25 = 2 (narrowest, most dangerous).
Drug Z: 200/20 = 10. Both X and Z share a TI of 10, and option C correctly identifies the calculation. Drug Y has the
narrowest TI and the highest risk of dose-related toxicity. TI is a population-based preclinical measure; the clinically
more useful parameter is the narrow therapeutic window (e.g., digoxin, warfarin, phenytoin) which requires
individualized monitoring.
Q6: A 47-year-old patient with opioid use disorder is started on buprenorphine for medication-assisted
treatment. Buprenorphine is described as a partial agonist at the mu-opioid receptor. Which
pharmacodynamic property BEST explains why buprenorphine is preferred over full agonists in office-based
treatment?
A. It produces greater euphoria, improving treatment retention
B. It has a ceiling effect on respiratory depression, reducing overdose risk [CORRECT]
C. It lacks any affinity for the mu receptor, preventing reinforcement
D. It undergoes zero-order kinetics, producing a flat dose-response curve
Correct Answer: B
Rationale: Buprenorphine is a high-affinity partial agonist at the mu receptor. Its partial agonism produces a ceiling
effect on respiratory depression, lowering fatal overdose risk while still providing enough agonism to suppress
withdrawal and craving. Option A is incorrect; partial agonists produce less euphoria than full agonists like heroin or
methadone, which is desirable. Option C is wrong because buprenorphine must bind the mu receptor to be effective.
Option D confuses pharmacokinetic (zero-order) with pharmacodynamic (ceiling) properties.
Q7: A 60-year-old male with endocarditis is receiving vancomycin. As the prescriber increases the dose, the
plasma concentration rises disproportionately (more than proportional to the dose increase). Which
pharmacokinetic mechanism BEST explains this observation?
A. First-order elimination kinetics
B. Zero-order (Michaelis-Menten) elimination kinetics with saturation of tubular secretion [CORRECT]
C. Enhanced renal tubular reabsorption at higher concentrations
D. Increased plasma protein binding at higher concentrations
Correct Answer: B
Rationale: Vancomycin is eliminated primarily by glomerular filtration but also undergoes active proximal tubular
secretion via OAT transporters. At higher doses, tubular transporters saturate, producing nonlinear accumulation. The
clinical implication is that small dose increases can produce disproportionate concentration rises, necessitating
trough-based therapeutic drug monitoring (10-20 mcg/mL for most infections; 15-20 mcg/mL for serious MRSA
infections). Option A describes linear kinetics, contradicting the stem. Option C is not relevant to vancomycin. Option D
would decrease free fraction but would not cause disproportionate accumulation.
NURS 6521 Midterm - Set 3 - 100 Questions Page 3 Confidential - For Examination Use
, WALDEN UNIVERSITY | NURS 6521 - Advanced Pharmacology Midterm Exam - Spring 2026/2027 - Set 3
Q8: A 72-year-old male with cirrhosis is started on sertraline 50 mg daily for depression. Compared with a
healthy adult, which pharmacokinetic change is MOST expected in this patient?
A. Increased activity of CYP2C9, accelerating sertraline clearance
B. Reduced hepatic first-pass metabolism, raising bioavailability and plasma concentrations [CORRECT]
C. Increased plasma albumin, lowering free drug fraction
D. Enhanced renal excretion compensating for hepatic impairment
Correct Answer: B
Rationale: Cirrhosis reduces functional hepatocyte mass and portosystemic shunting decreases first-pass metabolism,
raising oral bioavailability of highly extracted drugs such as sertraline, morphine, and propranolol. The reduced
clearance also prolongs half-life. Option A is wrong; cirrhosis decreases, not increases, CYP activity. Option C is
incorrect; albumin synthesis falls in cirrhosis, raising free fraction of protein-bound drugs. Option D is incorrect; renal
function is often concurrently impaired in hepatorenal syndrome, not enhanced.
Q9: A pharmacist counsels a patient that tetracycline should not be co-administered with dairy products or
antacids containing calcium, magnesium, or aluminum. Which pharmacokinetic interaction is responsible?
A. Increased first-pass metabolism by CYP3A4
B. Chelation in the GI tract reducing drug absorption [CORRECT]
C. Displacement from plasma protein binding sites
D. Competition for renal tubular secretion
Correct Answer: B
Rationale: Tetracyclines form insoluble chelates with polyvalent cations (Ca2+, Mg2+, Al3+, Fe2+/Fe3+, Zn2+).
Chelation in the intestinal lumen prevents absorption, reducing bioavailability by 50% or more. Patients should space
dosing 2 hours before or 6 hours after dairy, antacids, iron, or calcium supplements. Option A describes metabolism, not
absorption. Option C involves protein binding but is irrelevant to the GI interaction. Option D is incorrect; tetracyclines
are excreted renally but not via competition for OAT/OCT transporters in a clinically significant way.
Q10: A patient with epilepsy has a phenytoin level of 6 mcg/mL (therapeutic range 10-20 mcg/mL) on a 300
mg daily dose. The prescriber increases the dose to 400 mg daily. Two weeks later, the level is 32 mcg/mL.
Which pharmacokinetic principle explains this disproportionate increase?
A. Linear first-order elimination
B. Saturable Michaelis-Menten metabolism with nonlinear kinetics [CORRECT]
C. Induction of hepatic CYP2C9
D. Increased glomerular filtration of phenytoin
Correct Answer: B
Rationale: Phenytoin is the classic example of nonlinear Michaelis-Menten kinetics. At low doses, metabolism is
first-order because concentrations are below Km (~4 mg/L). As dose approaches Vmax (which is limited by saturable
CYP2C9 metabolism), small dose increases cause disproportionate concentration rises. The recommended empiric dose
adjustment is no more than 25-50 mg at a time. Option A is contradicted by the disproportionate rise. Option C is wrong;
phenytoin is not a clinically relevant CYP2C9 inducer (carbamazepine is). Option D is wrong because phenytoin is
metabolized, not renally excreted unchanged.
NURS 6521 Midterm - Set 3 - 100 Questions Page 4 Confidential - For Examination Use
Walden University
NURS 6521: Advanced Pharmacology
Midterm Examination - Spring 2026/2027
Set 3 - Complete Questions and Answers
Total Questions: 100 | Format: Multiple Choice (4 options) | Cognitive Levels: 25% Recall, 55% Application, 20% Analysis
Aligned with 2026-2027 Advanced Practice Nursing (APN) Pharmacology Competencies and current FDA prescribing
guidelines
Examination Instructions: Each item contains a clinical scenario or pharmacology concept followed by four options (A-D).
Select the SINGLE most appropriate answer. Rationales follow each question explaining why the correct option is right
and why each distractor is wrong, including relevant pharmacokinetic principles, pharmacodynamic mechanisms,
patient-specific factors, monitoring parameters, and evidence-based prescribing guidelines. Items marked [CORRECT]
identify the designated answer; rationales cite current FDA black box warnings, Beers Criteria (2023), GDMT heart failure
guidelines (AHA/ACC 2022 updated), ADA Standards of Care (2024-2025), and CDC Antimicrobial Stewardship guidance.
Section 1: Pharmacokinetics and Pharmacodynamics (Q1-Q15) - Absorption, Distribution,
Metabolism, Excretion, and Receptor Theory
Q1: A 68-year-old female is prescribed propranolol 40 mg PO daily for essential hypertension. Compared
with the same dose given intravenously, the oral dose produces a significantly lower peak plasma
concentration. Which pharmacokinetic property BEST explains this observation?
A. The drug undergoes extensive first-pass hepatic metabolism, reducing systemic bioavailability
[CORRECT]
B. Propranolol is highly ionized in the gastric lumen, preventing absorption across enterocytes
C. The drug exhibits a large volume of distribution, sequestering it in adipose tissue
D. P-glycoprotein efflux at the renal tubule accelerates elimination after oral dosing
Correct Answer: A
Rationale: Bioavailability (F) describes the fraction of administered drug reaching systemic circulation unchanged.
Propranolol is a high-extraction-ratio drug metabolized extensively by hepatic CYP2D6 and CYP1A2 during first-pass
metabolism, so oral bioavailability is only about 25-35% versus 100% IV. Option B is incorrect because propranolol is a
weak base that is sufficiently lipophilic in its nonionized fraction to cross enterocytes. Option C confuses distribution
with bioavailability; Vd affects concentration at steady state but not the fraction reaching circulation. Option D describes
a post-absorption elimination process, not the difference between PO and IV peak concentrations.
NURS 6521 Midterm - Set 3 - 100 Questions Page 1 Confidential - For Examination Use
,WALDEN UNIVERSITY | NURS 6521 - Advanced Pharmacology Midterm Exam - Spring 2026/2027 - Set 3
Q2: A patient receiving IV nitroglycerin for unstable angina is switched to an oral nitrate preparation. The
prescriber selects isosorbide dinitrate rather than nitroglycerin tablets. Which pharmacokinetic rationale
supports this decision?
A. Nitroglycerin undergoes nearly complete first-pass hepatic metabolism, rendering oral tablets ineffective
[CORRECT]
B. Isosorbide dinitrate has a larger volume of distribution, prolonging its half-life
C. Nitroglycerin is unstable in gastric pH and degrades before absorption
D. Isosorbide dinitrate does not require hepatic activation to become pharmacologically active
Correct Answer: A
Rationale: Nitroglycerin has an oral bioavailability of less than 1% because of extensive first-pass metabolism by
hepatic organic nitrate reductases, so oral nitroglycerin tablets are clinically useless. Isosorbide dinitrate and mononitrate
are not substrates for these high-capacity enzymes and therefore retain oral bioavailability. Option B incorrectly
attributes the choice to Vd rather than bioavailability. Option C is incorrect; nitroglycerin is not primarily degraded by
gastric acid. Option D is true but irrelevant; nitroglycerin itself is active and requires no prodrug conversion.
Q3: A 55-year-old male weighing 70 kg receives a 500 mg loading dose of phenytoin IV. The drug's volume of
distribution is 0.7 L/kg. Assuming complete bioavailability and instant distribution, what is the EXPECTED
peak plasma concentration?
A. 5.0 mg/L (5 mcg/mL)
B. 7.1 mg/L (7.1 mcg/mL)
C. 10.2 mg/L (10.2 mcg/mL) [CORRECT]
D. 20.0 mg/L (20 mcg/mL)
Correct Answer: C
Rationale: Using Cp = Dose / Vd: Vd = 0.7 L/kg x 70 kg = 49 L. Cp = 500 mg / 49 L = 10.2 mg/L (10.2 mcg/mL). This
places the patient within the lower end of the therapeutic range for phenytoin (10-20 mcg/mL). Option A miscalculates
by applying Vd incorrectly. Option B reflects a math error (failing to divide dose by Vd). Option D would be the upper
limit of the therapeutic range but corresponds to about 1000 mg. Therapeutic drug monitoring is critical for phenytoin
because of its nonlinear Michaelis-Menten kinetics.
Q4: A patient with chronic atrial fibrillation is started on digoxin 0.25 mg PO daily without a loading dose.
The drug's half-life is approximately 36 hours. Approximately how long will it take to reach steady-state
plasma concentrations?
A. 12 hours (one third of a half-life)
B. 36 hours (one half-life)
C. 72-108 hours (two to three half-lives)
D. 180-216 hours (five to six half-lives) [CORRECT]
Correct Answer: D
Rationale: The general pharmacokinetic principle is that steady state is achieved after approximately 4-5 half-lives of
repeated dosing. For digoxin, with t1/2 = 36 hours, steady state is reached in roughly 5 x 36 = 180 hours, or about 7.5
days. Options A, B, and C are too short; partial accumulation occurs but not steady state. Without a loading dose, the
patient requires nearly a week before therapeutic digoxin levels are attained, which is why loading doses (0.5-1.0 mg in
divided doses) are used when rapid digitalization is required.
NURS 6521 Midterm - Set 3 - 100 Questions Page 2 Confidential - For Examination Use
,WALDEN UNIVERSITY | NURS 6521 - Advanced Pharmacology Midterm Exam - Spring 2026/2027 - Set 3
Q5: Three investigational compounds are compared for safety margin. Drug X has an LD50 of 80 mg and
ED50 of 8 mg; Drug Y has LD50 of 50 mg and ED50 of 25 mg; Drug Z has LD50 of 200 mg and ED50 of 20
mg. Which statement BEST reflects the relative safety of these agents?
A. Drug X has the widest TI and is the safest agent
B. Drug Y is safest because it has the lowest LD50
C. Drug Z has a TI of 10 and is among the safer agents [CORRECT]
D. All three drugs have equivalent safety profiles
Correct Answer: C
Rationale: Therapeutic Index (TI) = LD50 / ED50. Drug X: 80/8 = 10. Drug Y: 50/25 = 2 (narrowest, most dangerous).
Drug Z: 200/20 = 10. Both X and Z share a TI of 10, and option C correctly identifies the calculation. Drug Y has the
narrowest TI and the highest risk of dose-related toxicity. TI is a population-based preclinical measure; the clinically
more useful parameter is the narrow therapeutic window (e.g., digoxin, warfarin, phenytoin) which requires
individualized monitoring.
Q6: A 47-year-old patient with opioid use disorder is started on buprenorphine for medication-assisted
treatment. Buprenorphine is described as a partial agonist at the mu-opioid receptor. Which
pharmacodynamic property BEST explains why buprenorphine is preferred over full agonists in office-based
treatment?
A. It produces greater euphoria, improving treatment retention
B. It has a ceiling effect on respiratory depression, reducing overdose risk [CORRECT]
C. It lacks any affinity for the mu receptor, preventing reinforcement
D. It undergoes zero-order kinetics, producing a flat dose-response curve
Correct Answer: B
Rationale: Buprenorphine is a high-affinity partial agonist at the mu receptor. Its partial agonism produces a ceiling
effect on respiratory depression, lowering fatal overdose risk while still providing enough agonism to suppress
withdrawal and craving. Option A is incorrect; partial agonists produce less euphoria than full agonists like heroin or
methadone, which is desirable. Option C is wrong because buprenorphine must bind the mu receptor to be effective.
Option D confuses pharmacokinetic (zero-order) with pharmacodynamic (ceiling) properties.
Q7: A 60-year-old male with endocarditis is receiving vancomycin. As the prescriber increases the dose, the
plasma concentration rises disproportionately (more than proportional to the dose increase). Which
pharmacokinetic mechanism BEST explains this observation?
A. First-order elimination kinetics
B. Zero-order (Michaelis-Menten) elimination kinetics with saturation of tubular secretion [CORRECT]
C. Enhanced renal tubular reabsorption at higher concentrations
D. Increased plasma protein binding at higher concentrations
Correct Answer: B
Rationale: Vancomycin is eliminated primarily by glomerular filtration but also undergoes active proximal tubular
secretion via OAT transporters. At higher doses, tubular transporters saturate, producing nonlinear accumulation. The
clinical implication is that small dose increases can produce disproportionate concentration rises, necessitating
trough-based therapeutic drug monitoring (10-20 mcg/mL for most infections; 15-20 mcg/mL for serious MRSA
infections). Option A describes linear kinetics, contradicting the stem. Option C is not relevant to vancomycin. Option D
would decrease free fraction but would not cause disproportionate accumulation.
NURS 6521 Midterm - Set 3 - 100 Questions Page 3 Confidential - For Examination Use
, WALDEN UNIVERSITY | NURS 6521 - Advanced Pharmacology Midterm Exam - Spring 2026/2027 - Set 3
Q8: A 72-year-old male with cirrhosis is started on sertraline 50 mg daily for depression. Compared with a
healthy adult, which pharmacokinetic change is MOST expected in this patient?
A. Increased activity of CYP2C9, accelerating sertraline clearance
B. Reduced hepatic first-pass metabolism, raising bioavailability and plasma concentrations [CORRECT]
C. Increased plasma albumin, lowering free drug fraction
D. Enhanced renal excretion compensating for hepatic impairment
Correct Answer: B
Rationale: Cirrhosis reduces functional hepatocyte mass and portosystemic shunting decreases first-pass metabolism,
raising oral bioavailability of highly extracted drugs such as sertraline, morphine, and propranolol. The reduced
clearance also prolongs half-life. Option A is wrong; cirrhosis decreases, not increases, CYP activity. Option C is
incorrect; albumin synthesis falls in cirrhosis, raising free fraction of protein-bound drugs. Option D is incorrect; renal
function is often concurrently impaired in hepatorenal syndrome, not enhanced.
Q9: A pharmacist counsels a patient that tetracycline should not be co-administered with dairy products or
antacids containing calcium, magnesium, or aluminum. Which pharmacokinetic interaction is responsible?
A. Increased first-pass metabolism by CYP3A4
B. Chelation in the GI tract reducing drug absorption [CORRECT]
C. Displacement from plasma protein binding sites
D. Competition for renal tubular secretion
Correct Answer: B
Rationale: Tetracyclines form insoluble chelates with polyvalent cations (Ca2+, Mg2+, Al3+, Fe2+/Fe3+, Zn2+).
Chelation in the intestinal lumen prevents absorption, reducing bioavailability by 50% or more. Patients should space
dosing 2 hours before or 6 hours after dairy, antacids, iron, or calcium supplements. Option A describes metabolism, not
absorption. Option C involves protein binding but is irrelevant to the GI interaction. Option D is incorrect; tetracyclines
are excreted renally but not via competition for OAT/OCT transporters in a clinically significant way.
Q10: A patient with epilepsy has a phenytoin level of 6 mcg/mL (therapeutic range 10-20 mcg/mL) on a 300
mg daily dose. The prescriber increases the dose to 400 mg daily. Two weeks later, the level is 32 mcg/mL.
Which pharmacokinetic principle explains this disproportionate increase?
A. Linear first-order elimination
B. Saturable Michaelis-Menten metabolism with nonlinear kinetics [CORRECT]
C. Induction of hepatic CYP2C9
D. Increased glomerular filtration of phenytoin
Correct Answer: B
Rationale: Phenytoin is the classic example of nonlinear Michaelis-Menten kinetics. At low doses, metabolism is
first-order because concentrations are below Km (~4 mg/L). As dose approaches Vmax (which is limited by saturable
CYP2C9 metabolism), small dose increases cause disproportionate concentration rises. The recommended empiric dose
adjustment is no more than 25-50 mg at a time. Option A is contradicted by the disproportionate rise. Option C is wrong;
phenytoin is not a clinically relevant CYP2C9 inducer (carbamazepine is). Option D is wrong because phenytoin is
metabolized, not renally excreted unchanged.
NURS 6521 Midterm - Set 3 - 100 Questions Page 4 Confidential - For Examination Use
